American Association for Cancer Research

sorry, we can't preview this file

ccr-22-3240_supplementary_table_s2_summary_of_crowdsourcing_sumbissions_received_suppts2.docx (65.14 kB)

Supplementary Table S2: Summary of Crowdsourcing Sumbissions Received from FDA Oncology Center of Excellence Crowdsourcing Initiative: Outreach to the Scientific Community to Identify Research Questions for Pooled Analyses of Oncology Clinical Trial Data

Download (65.14 kB)
journal contribution
posted on 2023-04-18, 13:20 authored by Julie A. Schneider, Julia Eckstein, Kirsten B. Goldberg, Mark C. Ascione, Thamar Bailey, Kimberly Taylor, Aisha M. Coffey, Darshini Satchi, Howard Philips, Rajeshwari Sridhara, Abhilasha Nair, Richard Pazdur, Marc R. Theoret

Summary of Crowdsourcing Submissions Received



The FDA Oncology Center of Excellence recently launched a crowdsourcing pilot to request ideas from the scientific community for research questions that FDA could address with pooled analyses of clinical trial data submitted to the agency for regulatory purposes. This effort builds on FDA's track record of publishing pooled analyses to explore scientific questions that cannot be addressed in a single trial due to limited sample size. The research crowdsourcing pilot tested a new approach for obtaining external input on regulatory science activities, because FDA is generally unable to share patient-level data outside of the agency due to federal disclosure laws and regulations protecting different types of data submitted in regulatory applications. We received 29 submissions over the 28-day crowdsourcing campaign, including one research idea that we are exploring for possible follow-up. Based on our experience with this pilot, we learned that crowdsourcing is a promising new approach to gather external input and feedback. We identified opportunities to build understanding in the external oncology community about the types of data typically included in regulatory applications and expand the dissemination of published FDA pooled analyses to help inform future drug development and clinical practice.

Usage metrics

    Clinical Cancer Research





    Ref. manager